(Q37260294)

19 August 2017

1 reference

title

Aberrant signal transduction pathways in myeloproliferative neoplasms (English)

1 reference

19 August 2017

J Kota

1

1 reference

19 August 2017

N Caceres

series ordinal

2

1 reference

19 August 2017

S N Constantinescu

series ordinal

3

1 reference

19 August 2017

4 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

22

1 reference

19 August 2017

10

1 reference

19 August 2017

1828-1840

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2008.236

19 August 2017

0 references

cites work

20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

STAT3 is constitutively active in some patients with Polycythemia rubra vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Expression of Bcl-x in erythroid precursors from patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Polycythaemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Increased expression of the INK4a/ARF locus in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Identification of an acquired JAK2 mutation in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The hematopoietic stem compartment consists of a limited number of discrete stem cell subsets

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Polycythemia vera is not initiated by JAK2V617F mutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The N-termini of FAK and JAKs contain divergent band 4.1 domains

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Janus kinases affect thrombopoietin receptor cell surface localization and stability

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Inactivation of erythropoietin receptor function by point mutations in a region having homology with other cytokine receptors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Regulation of the Jak2 tyrosine kinase by its pseudokinase domain

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Thrombopoietin signal transduction requires functional JAK2, not TYK2

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Cytokine receptor signal transduction and the control of hematopoietic cell development

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Jak2: normal function and role in hematopoietic disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Requirement for mitogen-activated protein kinase activation in the response of embryonic stem cell-derived hematopoietic cells to thrombopoietin in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Downregulation of signal transducer and activator of transcription 5 (STAT5) in CD34+ cells promotes megakaryocytic development, whereas activation of STAT5 drives erythropoiesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Activating mutations in human acute megakaryoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Characterization of murine JAK2V617F-positive myeloproliferative disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Determination of the transphosphorylation sites of Jak2 kinase.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Kinase activation through dimerization by human SH2-B

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

SOCS proteins, cytokine signalling and immune regulation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

JAK kinases overexpression promotes in vitro cell transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Transcriptional regulation of erythropoiesis: an affair involving multiple partners

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Imatinib effect on growth and signal transduction in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF- 1 in the development of myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

JAK signaling globally counteracts heterochromatic gene silencing

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Identification of JAK/STAT signalling components by genome-wide RNA interference.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Comparing the DNA hypermethylome with gene mutations in human colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Epigenetic control of PRV-1 expression on neutrophils.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.236

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.236

1 reference

Dimensions Publication ID

19 August 2017

0 references

1 reference